"Coenzyme Q10 Formulations In The Treatment And Prevention Of Epidermolysis Bullosa" in Patent Application Approval Process (USPTO 20230142060).

The method of claim 1, wherein administration of the pharmaceutical composition comprising CoQ10 to an affected area containing at least one blister and/or wound for a treatment duration of about four weeks results in at least 70% reduction in the size of the affected area containing at least one blister and/or wound. The method of claim 25, wherein administration of the pharmaceutical composition comprising CoQ10 to an affected area containing at least one blister and/or wound for a treatment duration of about four weeks results in at least 70% reduction in the size of the affected area containing at least one blister and/or wound. A method of treating a wound associated with Epidermolysis Bullosa (EB) in a subject in need thereof, comprising topical administration of a pharmaceutical composition comprising a therapeutically effective amount of CoQ10 to the wound in the subject. Traditionally, it was asserted that there were three major groups of inherited EB, namely EB simplex, junctional EB and dystrophic EB; based on the ultrastructural level within which skin cleaves and blisters. [Extracted from the article]